• FY26 revenue grew 159% year-on-year to $169k
• Successful capital raise of $30m, $41.2m in cash and term deposits
• Guardion device and LifeChain software delivered, FDA approval expected 1H FY27
• Partnerships with key U.S. blood collection sites and IMV Technologies
• U.S. operations established, CEO relocating to U.S. in 1H FY27

VFY.ASX presented its FY26 results, highlighting significant growth and progress across its product, market, and operations. The company reported a 159% year-on-year increase in revenue to $169k, driven by strong performance in animal health and other income, including grants. VFY successfully delivered its Guardion freezing device and LifeChain software, achieving key regulatory milestones and commencing FDA validation work. Strategic partnerships were secured with major U.S. blood collection sites and IMV Technologies, positioning VFY for future growth. The company also established U.S. operations, with the CEO relocating to the U.S. in the first half of FY27. VFY's financial position remains strong, with $41.2m in cash and term deposits following a successful capital raise of $30m, providing the necessary funding to support its growth initiatives.

VFY expects to continue scaling its manufacturing operations and expanding its U.S. presence, with a focus on building out CGT deployments and further commercializing its Guardion device and LifeChain software.